ScholarLens Back to search
2020•American family physicianRequires access

ACR Guideline for Managing Patients with Degenerative Joint Disease of the Hand, Knee, and Hip.

Henry C Barry

Open publisher page 0 citations

Abstract

This meta-analysis found no evidence that the monoclonal antibody denosumab reduces the risk of fracture more than bisphosphonates.

About this research paper

What this paper is about

This meta-analysis found no evidence that the monoclonal antibody denosumab reduces the risk of fracture more than bisphosphonates.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This meta-analysis found no evidence that the monoclonal antibody denosumab reduces the risk of fracture more than bisphosphonates.

Key concepts: Medicine, Guideline, Joint disease, Physical therapy, Physical medicine and rehabilitation, Joint (building), Osteoarthritis, Alternative medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
ACR Guideline for Managing Patients with Degenerative Joint Disease of the Hand, Knee, and Hip. — Research Paper | ScholarLens